Associate News Editor, Senior Medical Journalist
Todd Neale is an Associate News Editor and Senior Medical Journalist at TCTMD. With a strong focus on medicine and healthcare, he covers a range of topics including cardiology, the coronavirus, AI in healthcare, social issues, and FDA regulations. Todd's work has been featured in TCTMD, showcasing his expertise in medical specialties and the healthcare system.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Todd Neale's articles primarily focus on healthcare and pharmaceuticals, with a strong emphasis on citing data. He covers topics related to cardiology, heart disease, medical research, cardiac arrhythmias, and hypertension.
Given the heavy reliance on data in his coverage, Todd would likely be interested in pitches from reputable sources who can provide access to or interpret new clinical trial results or studies within the field of cardiology and related areas. This could include researchers leading groundbreaking studies or experts capable of providing context around complex scientific findings within these domains.
It is important for potential contributors to have a solid grasp of statistical methods and an ability to communicate about scientific evidence in clear terms when reaching out to Todd.
This information evolves through artificial intelligence and human feedback. Improve this profile .
EPs in the US do more LAAO procedures than interventional cardiologists: a new analysis digs into whose outcomes are best.
The Affera mapping and ablation system is the first on the market that can deliver both pulsed-field and radiofrequency energy.
Select patients with moderate AS may benefit, but in general it's okay to wait for severe stenosis, Nicolas Van Mieghem says.
A clinically relevant question without a definitive answer means larger trials are needed to provide clarity, the investigators say.
The trial adds much-needed randomized data to an area where it's been lacking. More trials are coming.
The result calls into question the prospects of FDA approval for the Acurate neo2 valve, which is already in use globally.
The analysis wasn't prespecified, and with no clear explanation, the field awaits insights from the larger BHF PROTECT-TAVI trial.
The latest data show healthy compensation levels and resilience, but the impact of ownership changes remains unclear.
There's no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away at it.
Weight regain and worsening cardiometabolic status are real threats. Too few physicians pay notice, a new viewpoint argues.
(833) 317-6278 
